EMAIL THIS PAGE TO A FRIEND

Journal of immunology (Baltimore, Md. : 1950)

Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes.


PMID 25716997

Abstract

Despite successful combined antiretroviral therapy, ∼ 60% of HIV-infected people exhibit HIV-associated neurocognitive disorders (HAND). CCL2 is elevated in the CNS of infected people with HAND and mediates monocyte influx into the CNS, which is critical in neuroAIDS. Many HIV-infected opiate abusers have increased neuroinflammation that may augment HAND. Buprenorphine is used to treat opiate addiction. However, there are few studies that examine its impact on HIV neuropathogenesis. We show that buprenorphine reduces the chemotactic phenotype of monocytes. Buprenorphine decreases the formation of membrane projections in response to CCL2. It also decreases CCL2-induced chemotaxis and mediates a delay in reinsertion of the CCL2 receptor, CCR2, into the cell membrane after CCL2-mediated receptor internalization, suggesting a mechanism of action of buprenorphine. Signaling pathways in CCL2-induced migration include increased phosphorylation of p38 MAPK and of the junctional protein JAM-A. We show that buprenorphine decreases these phosphorylations in CCL2-treated monocytes. Using DAMGO, CTAP, and Nor-BNI, we demonstrate that the effect of buprenorphine on CCL2 signaling is opioid receptor mediated. To identify additional potential mechanisms by which buprenorphine inhibits CCL2-induced monocyte migration, we performed proteomic analyses to characterize additional proteins in monocytes whose phosphorylation after CCL2 treatment was inhibited by buprenorphine. Leukosialin and S100A9 were identified and had not been shown previously to be involved in monocyte migration. We propose that buprenorphine limits CCL2-mediated monocyte transmigration into the CNS, thereby reducing neuroinflammation characteristic of HAND. Our findings underscore the use of buprenorphine as a therapeutic for neuroinflammation as well as for addiction.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

1570428
2-Propanol, United States Pharmacopeia (USP) Reference Standard
C3H8O
PHR1072
2-Propanol, Pharmaceutical Secondary Standard; Certified Reference Material
C3H8O
91237
2-Propanol, analytical standard
C3H8O
90872
Acetone, analytical standard
C3H6O
1006801
Acetone, United States Pharmacopeia (USP) Reference Standard
C3H6O
PHR1219
Acetone, Pharmaceutical Secondary Standard; Certified Reference Material
C3H6O
48358
Acetone solution, certified reference material, 2000 μg/mL in methanol: water (9:1)
C3H6O
B0126
Bromophenol Blue
C19H10Br4O5S
114391
Bromophenol Blue, ACS reagent
C19H10Br4O5S
C6352
CTAP, ≥95%
C51H69N13O11S2
E7384
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt, ≥97% (HPLC)
C26H35N5O6
49897
Formate standard for IC, 1.000 g/L in H2O, analytical standard
CH2O2
06473
Formic acid solution, BioUltra, 1.0 M in H2O
CH2O2
1295607
Glycerin, United States Pharmacopeia (USP) Reference Standard
C3H8O3
PHR1020
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
C3H8O3
49779
Glycerol, tested according to Ph.Eur., anhydrous
C3H8O3
77067
Glycerol, analytical standard
C3H8O3
12146
Glycerol 3 M solution, 3 M
C3H8O3 · xH2O
I1149
Iodoacetamide, BioUltra
C2H4INO
I6125
Iodoacetamide, ≥99% (NMR), crystalline
C2H4INO
I5161
Iodoacetamide, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production
C2H4INO
71726
Sodium dodecyl sulfate, for ion pair chromatography, ≥99.0%
C12H25NaO4S
Y0000620
Sodium laurilsulfate, European Pharmacopoeia (EP) Reference Standard
C12H25NaO4S
74564
Trifluoroacetic acid, analytical standard
C2HF3O2
U0600000
Urea, European Pharmacopoeia (EP) Reference Standard
CH4N2O
1706698
Urea, United States Pharmacopeia (USP) Reference Standard
CH4N2O
56180
Urea, analytical standard
CH4N2O
51465
Urea, tested according to Ph.Eur.
CH4N2O
08582
Urea solution, for microbiology, 40% in H2O
CH4N2O